FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220793575> ?p ?o ?g. }

• W4220793575 endingPage "5379" @default.
• W4220793575 startingPage "5371" @default.
• W4220793575 abstract "Early palliative care improves patient quality of life and influences cancer care. The time frame of early has not been established. Eight quality measures reflect aggressive care at the end of life. We retrospectively reviewed patients who died with cancer between January 1, 2018, through December 31, 2019, and compared the timing of palliative care consultation, advance directives (AD), and home palliative care with aggressive care at the end of life (ACEOL).Patients without ACEOL indicators were compared to patients with one or more than one indicator of ACEOL. The proportion of patients who received palliative care, completed AD, and the timing of palliative care and AD (less than 30 days, 30-90 days, and greater than 90 days prior to death) was compared for patients who had ACEOL versus those who did not. Chi-square analysis was used for categorical data, one-way ANOVA for continuous variables, and odds ratio (OR) with confidence intervals (CI) was reported as a measure of effect size. A p value ≤ 0.05 was considered significant.1727 patients died, 46% were female, and the mean age was 69 (SD 11.91). Seventy-one percent had a palliative care consult, 26% completed AD, and 888 (51.4%) had at least one indicator of ACEOL. The most common indicator of ACEOL was new chemotherapy within 30 days of death, in 571 of 888 (64%) of patients experiencing ACEOL. ADs completed at any time reduced ACEOL (OR 0.80, 95%CI 0.64-0.99). Palliative care initiated at 30 days was associated with a greater risk of ACEOL (OR 5.32, 95% CI 3.94-7.18) and initiated between 30 and 90 days (OR 1.39, 95% CI 1.07-1.80) compared to no palliative care but was associated with reduced chemotherapy as an indicator of ACEOL when > 90 days (OR 0.46, 95% CI 0.38-0.57) before death.Completed ADs were associated with reduced chemotherapy in the last 30 days of life and reduced ICU admissions. This may reflect goals of care and end-of-life discussions and transition of care to comfort measures. Palliative care paradoxically when initiated within 90 days before death was associated with greater ACEOL compared to no palliative care. This may be due to consultation late in the course of illness with a focus on crisis management in patients frequently utilizing the health care system. There is an associated reduction in the use of chemotherapy in the last 30 days of life if palliative care is consulted 90 days prior to death.An initial palliative care consult greater than 90 days before death and ADs completed at any time during the disease trajectory was associated only with reduced chemotherapy in the last 30 days of life compared with no palliative care among the 7 ACEOL indicators. ADs were associated with reduced ICU admissions. Most palliative care consults occurred within 90 days of death and a palliative care consult within 90 days of death is not an optimal utilization of services." @default.
• W4220793575 created "2022-04-03" @default.
• W4220793575 creator A5005938693 @default.
• W4220793575 creator A5017540677 @default.
• W4220793575 creator A5031927345 @default.
• W4220793575 creator A5037931789 @default.
• W4220793575 creator A5054445312 @default.
• W4220793575 creator A5056074202 @default.
• W4220793575 creator A5065865860 @default.
• W4220793575 creator A5066858084 @default.
• W4220793575 creator A5067250306 @default.
• W4220793575 creator A5076678207 @default.
• W4220793575 creator A5084202064 @default.
• W4220793575 creator A5085405673 @default.
• W4220793575 date "2022-03-15" @default.
• W4220793575 modified "2023-10-16" @default.
• W4220793575 title "When does early palliative care influence aggressive care at the end of life?" @default.
• W4220793575 cites W1502426630 @default.
• W4220793575 cites W1568322542 @default.
• W4220793575 cites W1683357938 @default.
• W4220793575 cites W2016444653 @default.
• W4220793575 cites W2028440176 @default.
• W4220793575 cites W2039880732 @default.
• W4220793575 cites W2039903446 @default.
• W4220793575 cites W2045670277 @default.
• W4220793575 cites W2053525028 @default.
• W4220793575 cites W2068726835 @default.
• W4220793575 cites W2069811848 @default.
• W4220793575 cites W2078366991 @default.
• W4220793575 cites W2078669919 @default.
• W4220793575 cites W2084750201 @default.
• W4220793575 cites W2103903454 @default.
• W4220793575 cites W2129554678 @default.
• W4220793575 cites W2133768817 @default.
• W4220793575 cites W2135894244 @default.
• W4220793575 cites W2137325786 @default.
• W4220793575 cites W2138618575 @default.
• W4220793575 cites W2147016542 @default.
• W4220793575 cites W2148213673 @default.
• W4220793575 cites W2154104512 @default.
• W4220793575 cites W2160733129 @default.
• W4220793575 cites W2302801691 @default.
• W4220793575 cites W2328006801 @default.
• W4220793575 cites W2341091800 @default.
• W4220793575 cites W2476962513 @default.
• W4220793575 cites W2504299602 @default.
• W4220793575 cites W2546483967 @default.
• W4220793575 cites W2549006299 @default.
• W4220793575 cites W2560477237 @default.
• W4220793575 cites W2792386397 @default.
• W4220793575 cites W2800821513 @default.
• W4220793575 cites W2890895104 @default.
• W4220793575 cites W2902399992 @default.
• W4220793575 cites W2917880234 @default.
• W4220793575 cites W2921716672 @default.
• W4220793575 cites W2982082013 @default.
• W4220793575 cites W2982430016 @default.
• W4220793575 cites W2991058495 @default.
• W4220793575 cites W3018706414 @default.
• W4220793575 cites W3091900513 @default.
• W4220793575 cites W3109168897 @default.
• W4220793575 cites W3173595436 @default.
• W4220793575 doi "https://doi.org/10.1007/s00520-022-06954-2" @default.
• W4220793575 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35290511" @default.
• W4220793575 hasPublicationYear "2022" @default.
• W4220793575 type Work @default.
• W4220793575 citedByCount "2" @default.
• W4220793575 countsByYear W42207935752022 @default.
• W4220793575 countsByYear W42207935752023 @default.
• W4220793575 crossrefType "journal-article" @default.
• W4220793575 hasAuthorship W4220793575A5005938693 @default.
• W4220793575 hasAuthorship W4220793575A5017540677 @default.
• W4220793575 hasAuthorship W4220793575A5031927345 @default.
• W4220793575 hasAuthorship W4220793575A5037931789 @default.
• W4220793575 hasAuthorship W4220793575A5054445312 @default.
• W4220793575 hasAuthorship W4220793575A5056074202 @default.
• W4220793575 hasAuthorship W4220793575A5065865860 @default.
• W4220793575 hasAuthorship W4220793575A5066858084 @default.
• W4220793575 hasAuthorship W4220793575A5067250306 @default.
• W4220793575 hasAuthorship W4220793575A5076678207 @default.
• W4220793575 hasAuthorship W4220793575A5084202064 @default.
• W4220793575 hasAuthorship W4220793575A5085405673 @default.
• W4220793575 hasBestOaLocation W42207935752 @default.
• W4220793575 hasConcept C121608353 @default.
• W4220793575 hasConcept C126322002 @default.
• W4220793575 hasConcept C156957248 @default.
• W4220793575 hasConcept C159110408 @default.
• W4220793575 hasConcept C194828623 @default.
• W4220793575 hasConcept C2779526319 @default.
• W4220793575 hasConcept C2779951463 @default.
• W4220793575 hasConcept C2780879335 @default.
• W4220793575 hasConcept C2991975920 @default.
• W4220793575 hasConcept C2994186709 @default.
• W4220793575 hasConcept C42219234 @default.
• W4220793575 hasConcept C44249647 @default.
• W4220793575 hasConcept C518773536 @default.
• W4220793575 hasConcept C71924100 @default.
• W4220793575 hasConceptScore W4220793575C121608353 @default.

• next